Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Hoppe, R. Advani, W. Ai, R. Ambinder, P. Aoun, C. Bello, C. Benitez, P. Bierman, K. Blum, Robert Chen, B. Dabaja, A. Forero, L. Gordon, F. Hernandez-Ilizaliturri, E. Hochberg, Jiayi Huang, P. Johnston, N. Khan, D. Maloney, P. Mauch, M. Metzger, J. Moore, D. Morgan, C. Moskowitz, C. Mulroney, M. Poppe, R. Rabinovitch, S. Seropian, C. Tsien, J. Winter, J. Yahalom, J. Burns, Hema Sundar (2015)
Hodgkin lymphoma, version 2.2015.Journal of the National Comprehensive Cancer Network : JNCCN, 13 5
P. Senter, E. Sievers (2012)
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphomaNature Biotechnology, 30
Long - term follow - up results of an ongoing pivotal study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma ( HL )
RT Hoppe, RH Advani, WZ Ai (2012)
Hodgkin lymphoma, version 2.2012 featured updates of the NCCN guidelinesJ Natl Compr Cancer Net, 10
(2008)
Defining a population of Hodgkin lymphoma patients for novel therapeutics : an international effort
A. Younes, N. Bartlett, J. Leonard, D. Kennedy, C. Lynch, E. Sievers, A. Forero-Torres (2010)
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.The New England journal of medicine, 363 19
Á. Jóna, A. Younes (2010)
Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.Blood reviews, 24 6
A. Younes, A. Gopal, Scott Smith, S. Ansell, J. Rosenblatt, K. Savage, R. Ramchandren, N. Bartlett, B. Cheson, S. Vos, A. Forero-Torres, C. Moskowitz, J. Connors, A. Engert, E. Larsen, D. Kennedy, E. Sievers, Robert Chen (2012)
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 18
(2010)
Brentuximab vedo - tin ( SGN - 35 ) for relapsed CD 30 - positive lymphomas
R. Schwartz (2004)
Paul Ehrlich's magic bullets.The New England journal of medicine, 350 11
J. Katz, J. Janik, A. Younes (2011)
Brentuximab Vedotin (SGN-35)Clinical Cancer Research, 17
H. Earl (2012)
Reporting of adjuvant breast cancer trials: when is the right time?Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 1
A. Hochhaus, P. Schlag, N. Cordes, K. Höffken (2013)
Paul Ehrlichs „magic bullets“Der Onkologe, 19
A. Engert, D. Eichenauer, M. Dreyling (2008)
Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 20 Suppl 4
P. Carter, P. Senter (2008)
Antibody-Drug Conjugates for Cancer TherapyThe Cancer Journal, 14
A. Engert, D. Eichenauer, M. Dreyling (2010)
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 21 Suppl 5
Joyce Kane, Barbara Kasecamp, Candace Cottrell, Colleen Apostol, Lynn Billing, Donald List, Richard Jones, J. Fetting (2012)
Utilization of intensive care resources due to better communication of end-of-life issues.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 34_suppl
EL Sievers, PD Senter (2013)
Antibody-drug conjugates in cancer therapyAnn Rev Med, 64
We present a case of a 23-year-old female patient with relapsed classical Hodgkin lymphoma in reduced general condition. She was refractory after multiple lines of prior chemotherapy including autologous stem cell transplantation. By applying a targeted therapy concept using brentuximab vedotin (SGN-35), the patient experienced a rapid clinical improvement with loss of B symptoms immediately after the first treatment cycle. Elevated serum levels for C-reactive protein (CRP) and lactate dehydrogenase (LDH) returned to normal, and a significant improvement of hemoglobin levels were observed. Moreover, after administration of 16 cycles, the patient remains in complete remission, lasting now for > 15 months. Tolerability of treatment was excellent without evidence of infections or peripheral neuropathy. This case illustrates the clinical potential of brentuximab vedotin in patients with end-stage Hodgkin lymphoma who would otherwise have only limited treatment options.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Mar 29, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.